The 14-valent HPV vaccine is in the clinical trial stage, and from the current information there is no mention of the adapted population or the age group to be vaccinated. There are currently three HPV vaccines on the market: bivalent, quadrivalent and nine-valent vaccines. 1. The bivalent vaccine targets HPV-16/18 types, and the age of the vaccinated population is from 9 to 45 years old, according to the process of 0, 1, and 6 months to be vaccinated. 2. Quadrivalent vaccine targets HPV-16/18/6/11, suitable for women aged 9 to 45 years old, and is administered in accordance with the 0, 2, 6 month process. 3. Nine-valent vaccine prevents HPV-16/18/6/11/31/33/45/52/58 types, suitable for women aged 16~26 years old, with 1 dose in each of the 0th, 2nd and 6th month. The 14-valent HPV vaccine is still in the clinical study stage, and there is no data on whether there is an age limit.